Ads
related to: what is acute myeloid leukemia- Dosing & Administration
Learn about dosing and
administration now
- Efficacy Data
Studied against the best available
therapies for myelofibrosis
- Dosing & Administration
Search results
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 5 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 17 hours agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
WTNH-TV New Haven· 5 hours agoThe Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) ...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 11 hours agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid ...
After 25 years selling Harleys, Gail Worth will soon close KC business. She has plans
Kansas City Star via Yahoo Finance· 8 hours ago“He was my best friend in my whole life,” Worth said of Adams, who died in April after battling ...
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and...
WJTV Jackson· 2 days agoIomab-B and Actimab-A are the only targeted radiotherapies in development for patients with relapsed/refractory acute myeloid leukemia
Apollomics shares target cut on Phase 3 study results By Investing.com
Investing.com· 6 days agoThe adjustment came in response to recently revealed Phase 3 study results which did not meet the...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 1 day agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Curis Announces Additional Data from TakeAim Leukemia Study
WRBL Columbus· 7 hours agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from ...
Researchers discover new target for potential leukemia therapy
Medical Xpress· 7 days agoThe study provides both mechanistic and preclinical evidence supporting the rapid initiation of...
Ads
related to: what is acute myeloid leukemia